– The vaccine maker saw its shares fall 4.3% after the company said it expects to report data from its Covid-19 vaccine trials involving 2- to 5-year-olds by March. The company could file for approval to vaccinate that age group if the data is supportive, it said in a statement.
Corporate profits are breaking records, what with their “inflation”
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: